Alto Neuroscience says Phase 2 ALTO-101 schizophrenia cognition study misses primary endpoint

Alto Neuroscience, Inc.

ANRO

0.00

Alto Neuroscience reported topline Phase 2 proof-of-concept results for ALTO-101 in cognitive impairment associated with schizophrenia.
Study failed to meet primary endpoints versus placebo, limiting near-term path to independent development in this indication.
More detailed results will be presented at a future medical conference.
Strategy shifts toward seeking partners for a once-daily modified-release oral ALTO-101 formulation developed to improve tolerability.
Pipeline focus moves to lead program ALTO-207, with Phase 2b initiation targeted for 1H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604011630BIZWIRE_USPR_____20260401_BW931058) on April 01, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.